24 news items
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
CADL
18 Jun 24
multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has
Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
CADL
14 Jun 24
microenvironment and the diversity of the tumor response to existing treatments. Using large patient datasets
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
yielded tumor response rates nearly triple historical results. Should the combination of pelareorep and mFOLFIRINOX produce a similarly positive
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
, and atezolizumab yielded tumor response rates nearly triple historical results. Should the combination of pelareorep and mFOLFIRINOX produce a similarly
Candel Therapeutics' (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers
CADL
7 Jun 24
to FDA-approved immune checkpoint inhibitor (ICI) treatments. Poor ICI treatment response has been
ipvia5xycsnugwmrouia2evfqbatb2v ysmwz0uaax8plyfj7fa40bxiee3
CADL
3 Jun 24
CAN-2409 administration. This reinforces the potential of CAN-2409 to activate a robust antitumoral immune response in patients with cancer also
k98 hss3uhwwsv6xa9o8mkhvci2p8kcw
CADL
KRYS
MRNS
24 May 24
), together with standard of care (SoC) in patients with stage III/IV non-small cell lung cancer (NSCLC) who are non-responsive to immune checkpoint
m1k7 xrp6qf75
AKAN
AKTS
BIOR
24 May 24
for Advanced Non-Small Cell Lung Cancer (NSCLC) in patients non-responsive to Immune Checkpoint Inhibitor (ICI) treatment at 2024 ASCO Annual Meeting
ueahdlz8
CADL
23 May 24
CAN-2409 treatment resulted in activation of the systemic immune response after two administrations of CAN-2409, including increased numbers
ldrgh 3m6652idnwofa
AZN
CADL
LTRN
23 May 24
within the Oncolytics team that improved response rates from the mFOLFIRINOX combination, compared
hbiw chnyq2f3s7j1k9z4d39nmf0kj
AZN
CADL
LTRN
23 May 24
. There is optimism within the Oncolytics team that improved response rates from the mFOLFIRINOX combination, compared
tex2d73ls tglew6vhdphx1q2gi3f6d9jqg2u478flg
CADL
20 May 24
-tumor immune response. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells
9d5fiy2jbi958 jfjjsxwvi8nww6bj7lakjmianj8qsn
ABVC
AMGN
CADL
15 May 24
demonstrates improvements in response rate over historical control trials, this treatment approach could move forward to a registration-enabling study
w4v2h6nqjptcxycw0ig71qp
ABVC
AMGN
CADL
15 May 24
combination demonstrates improvements in response rate over historical control trials, this treatment approach could move forward to a registration-enabling
ydhv5h1rgrtg rpu7al04vv74dbqiridbgoe3avhw
AZN
CADL
HALO
9 May 24
."
Notably, Oncolytics plans to evaluate the correlation between tumor responses and the expansion of tumor
n9lge2jzclugrnh80sbbvllsik56m7trri6gampc
AZN
CADL
HALO
9 May 24
."
Notably, Oncolytics plans to evaluate the correlation between tumor responses and the expansion
jdvwl95u6sff88uifl34q3ctncsqnbe4y
AZN
CADL
HALO
9 May 24
, Oncolytics plans to evaluate the correlation between tumor responses and the expansion of tumor-infiltrating lymphocytes (TILs
q3ptz89dj8jlf3csn48n6a6v31
AZN
CADL
HALO
9 May 24
, Oncolytics plans to evaluate the correlation between tumor responses and the expansion of tumor-infiltrating lymphocytes (TILs
19v2k29gmm8ko4ehybme6ib7i
CADL
11 Apr 24
the activation of a robust systemic anti-tumor immune response.About Orphan Drug DesignationOrphan Drug Designation is granted
oegb3es7cjcorjjuv l6i525k57s8nnly7z
CADL
9 Apr 24
Analytics suite, was shown to induce tertiary lymphoid structure formation, inhibit tumor growth, and improve response to immune checkpoint inhibitor